In an open-label phase II study (NCT03495882), the efficiency of the dual PD-1 and CTLA-4 checkpoint blockade inhibitors balstilimab and zalifrelimab was evaluated in patients with recurrent and/or metastatic CC. Here, CTLA4 is linked to cholangiocarcinoma.